MeHow Innovative Ltd. A

Meihao Medical released its 2026 interim report, with net profit attributable to the parent company of 124 million yuan, up 8.77% from the same period last year. The company's total operating revenue was 813 million yuan, up 10.97% year-on-year, achieving growth for two consecutive years. Net cash inflow from operating activities was 166 million yuan, up 48.27% year-on-year. The company's latest asset-liability ratio was 12.23%, gross margin was 40.88%, and diluted earnings per share was 0.16 yuan.

Meihao Medical released its 2026 interim report, showing first-half net profit attributable to the parent of 124 million yuan, up 8.8% year on year. Operating revenue was 813 million yuan, up 11.0% year on year. Net profit attributable to the parent after deducting non-recurring items was 120 million yuan, up 8.7% year on year. Net operating cash flow was 166 million yuan, up 48.3% year on year. Second-quarter operating revenue was 410 million yuan, down 6.2% year on year, while net profit attributable to the parent was 67.64 million yuan, up 8.4% year on year. The company said the design, development, manufacturing and sales of its main business and products are all in a normal state, and it continues to cooperate with global medical device companies to provide full-process services.

Mehow Medical recently added a core invention patent, with patent publication number CN122140259A, titled "Self-Generating Neural Electrode and Manufacturing Method Thereof," officially disclosed. The patent addresses the long-term implantation pain points of invasive brain-computer interfaces, innovatively achieving in-situ self-generating repair of electrodes, alleviating the problems of impedance rise and neural signal attenuation after implantation, and effectively enhancing the long-term working stability and biocompatibility of neural electrodes. Leveraging its mature precision manufacturing capabilities for implantable medical devices, Mehow Medical is deeply engaged in the invasive neural electrode track, reusing precision processing and biocompatible encapsulation technologies from cochlear implants, and laying out core implant components for brain-computer interfaces. It provides process development and mass production support for leading domestic BCI enterprises, with related electrode components already in small-batch supply. As the brain-computer interface industry accelerates toward clinical implementation, long-lasting implant electrodes, as key hardware in the industry chain, are expected to see sustained demand growth.

Brain-computer interface technology is accelerating its deployment, with related concept stocks showing strong performance. Innovative Medical has achieved three trading sessions with two limit-up moves. Meihao Medical stated that the company is deeply engaged in process exploration and technical cooperation with domestic downstream brain-computer interface clients, fully assisting them in moving from research and development validation to large-scale commercial deployment. Vishee Medical focuses on non-invasive technology routes, committed to building a full-cycle closed-loop system of diagnosis, treatment, and rehabilitation. Haige Communications has released its first self-developed consumer-grade product, the intelligent sleep aid device, which is currently in the market promotion stage.

On the morning of July 27, A-share brain-computer interface concept stocks broke out strongly, with stocks in the sector rising collectively during the session. Chuangxin Medical hit a three-day two-board pattern, Aipeng Medical recorded a 20 percent daily limit up, Hainan Haiyao recorded a 10 percent daily limit up and hit a four-day two-board pattern, while Meihao Medical, New Journey, Yingkang Life, Xiangyu Medical, and Sanbo Brain Hospital and other concept stocks followed the rally. On the news front, a Chinese research team recently released a new type of EEG signal acquisition device, achieving for the first time globally the synchronous collection of EEG signals from over a thousand people across different regions. This breakthrough marks a key step forward in neural large model training and general brain-computer interface technology research and development. Kaiyuan Securities stated that it remains bullish on innovative drugs and their industry chain, as well as national strategic emerging industries such as AI, brain-computer interfaces, and biomanufacturing.